Galmed Pharmaceuticals Ltd
GLMD1.190USD
-0.145-10.85%
Fechamento 11/04, 16:00（ET）Cotações atrasadas em 15 min
6.31MValor de mercado
PerdaP/L TTM
Mais detalhes de Galmed Pharmaceuticals Ltd Empresa
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Informações de Galmed Pharmaceuticals Ltd
Código da empresaGLMD
Nome da EmpresaGalmed Pharmaceuticals Ltd
Data de listagemMar 13, 2014
CEOMr. Allen Baharaff
Número de funcionários3
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 13
Endereço16 Tiomkin Street
CidadeTEL AVIV-YAFO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal6578317
Telefone97236938448
Sitehttps://www.galmedpharma.com
Código da empresaGLMD
Data de listagemMar 13, 2014
CEOMr. Allen Baharaff
Executivos da empresa Galmed Pharmaceuticals Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.94K
+31.44%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
6.28K
+20164.52%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
6.28K
+20164.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
6.25K
+36664.71%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
3.40K
+1148.16%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
3.12K
+7338.10%
Mr. Amir Poshinski
Mr. Amir Poshinski
Independent Director
Independent Director
3.12K
--
Dr. Carol L. Brosgart, M.D.
Dr. Carol L. Brosgart, M.D.
Independent Director
Independent Director
--
--
Mr. Marshall A. Heinberg, J.D.
Mr. Marshall A. Heinberg, J.D.
Independent Director
Independent Director
--
--
Dr. Liat Hayardeny, Ph.D.
Dr. Liat Hayardeny, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.94K
+31.44%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
6.28K
+20164.52%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
6.28K
+20164.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
6.25K
+36664.71%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
3.40K
+1148.16%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
3.12K
+7338.10%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Baharaff (Allen)
0.67%
Morgan Stanley & Co. LLC
0.61%
Schonfeld Strategic Advisors LLC
0.42%
Cambridge Investment Research Advisors, Inc.
0.18%
UBS Financial Services, Inc.
0.13%
Outro
97.98%
Investidores
Investidores
Proporção
Baharaff (Allen)
0.67%
Morgan Stanley & Co. LLC
0.61%
Schonfeld Strategic Advisors LLC
0.42%
Cambridge Investment Research Advisors, Inc.
0.18%
UBS Financial Services, Inc.
0.13%
Outro
97.98%
Tipos de investidores
Investidores
Proporção
Individual Investor
1.19%
Research Firm
0.65%
Hedge Fund
0.42%
Investment Advisor
0.34%
Outro
97.39%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
29
77.68K
1.42%
-11.92K
2025Q2
36
135.24K
2.48%
+20.85K
2025Q1
40
122.99K
5.45%
+7.20K
2024Q4
44
74.98K
4.98%
+4.09K
2024Q3
46
26.83K
4.31%
-41.91K
2024Q2
47
54.30K
10.41%
+4.14K
2024Q1
52
35.65K
7.07%
-49.52K
2023Q4
54
66.85K
19.98%
-30.97K
2023Q3
59
78.73K
21.96%
+19.78K
2023Q2
57
33.03K
13.93%
-6.52K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Baharaff (Allen)
36.94K
0.67%
+8.83K
+31.44%
Mar 21, 2025
Morgan Stanley & Co. LLC
33.48K
0.61%
+33.48K
--
Jun 30, 2025
Schonfeld Strategic Advisors LLC
23.19K
0.42%
-2.00K
-7.94%
Jun 30, 2025
Cambridge Investment Research Advisors, Inc.
10.13K
0.18%
+10.13K
--
Jun 30, 2025
UBS Financial Services, Inc.
6.90K
0.13%
+5.80K
+525.27%
Jun 30, 2025
Nehemya (Guy)
6.28K
0.11%
+6.25K
+20164.52%
Mar 21, 2025
Stenzler (Yohai)
6.28K
0.11%
+6.25K
+20164.52%
Mar 21, 2025
Cohen (Doron)
6.25K
0.11%
+6.23K
+36664.71%
Mar 21, 2025
Nir (Shmuel)
3.40K
0.06%
+3.12K
+1148.16%
Mar 21, 2025
Sidransky (David)
3.12K
0.06%
+3.08K
+7338.10%
Mar 21, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
Data
Tipo
Proporção
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
